查看“SRPK1 抑制剂”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>SRPK1 抑制剂</strong>（SRPK1 Inhibitors）是一类靶向 <strong>[[SRPK1]]</strong>（Serine/Arginine-Protein Kinase 1）的小分子药物。由于剪接因子 <strong>[[SRSF1]]</strong> 本身缺乏酶活性口袋难以直接成药，抑制其上游激酶 SRPK1 成为了阻断致癌剪接通路的最佳策略。SRPK1 负责磷酸化 SRSF1 的 RS 结构域，这是 SRSF1 从细胞质进入细胞核的“通行证”。SRPK1 抑制剂通过阻断这一过程，将 SRSF1 扣留在细胞质中，迫使癌细胞的剪接模式从“促癌型”（如生成 <strong>[[Bcl-xL]]</strong>）转变为“正常/抑癌型”（如生成 <strong>[[Bcl-xS]]</strong>），从而诱导肿瘤凋亡。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">SRPK1 抑制剂</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Targeting SRSF1 Pathway (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                [Image:SRPK1_inhibitor_mechanism_SRSF1_translocation]
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">机制：阻止 SRSF1 入核</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">药物概览</th>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">直接靶点</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[SRPK1]] 激酶 (ATP结合袋)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">间接靶点</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[SRSF1]] (阻断其磷酸化)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">代表药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">SRPIN340, SPHINX31</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">主要效应</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">纠正 [[可变剪接]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">适应症</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">前列腺癌, 白血病, 视网膜病变</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">开发阶段</th>
                    <td style="padding: 6px 12px; color: #b91c1c;">临床前 / 早期临床</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗原理：关上细胞核的大门</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        SRSF1 在肿瘤中扮演“剪接独裁者”的角色，但它必须进入细胞核才能发号施令。SRPK1 抑制剂利用了这一弱点：
    </p>

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>阻断核转运 (Nuclear Translocation)：</strong> 
            <br>SRSF1 的 C 端 RS 结构域富含丝氨酸。只有当这些丝氨酸被 SRPK1 大量磷酸化后，SRSF1 才能被转运蛋白（Transportin-SR）识别并拉入细胞核。抑制 SRPK1 会导致 SRSF1 处于低磷酸化状态，滞留在细胞质中降解。</li>
        <li style="margin-bottom: 12px;"><strong>重塑剪接图谱 (Splicing Switching)：</strong> 
            <br>一旦核内的 SRSF1 浓度下降，由其维持的“致癌剪接”就会崩溃。例如，[[BCL2L1]] 的剪接会自发转向生成促凋亡的 <strong>[[Bcl-xS]]</strong>，[[VEGF]] 的剪接会转向抗血管生成的 VEGF-b 型。这种“四两拨千斤”的效应能广泛杀伤癌细胞。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键药物管线</h2>
    
    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">药物名称</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">特性与机制</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床潜力</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">SRPIN340</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">第一代特异性 SRPK1/2 抑制剂。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">在白血病和抗病毒（如 HIV、新冠病毒利用宿主剪接）研究中显示活性。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">SPHINX31</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">新型强效抑制剂，对 SRPK1 的选择性极高。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #16a34a;">在前列腺癌、乳腺癌及<strong>视网膜黄斑变性</strong>（通过抑制 VEGF 剪接）中效果显著。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">SM08502</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">广谱 CLK/SRPK 抑制剂（口服）。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">已进入 I 期临床试验，治疗晚期实体瘤。</td>
            </tr>
        </table>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Gammons MV, et al. (2013).</strong> <em>SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization.</em> <strong>[[Cell Reports]]</strong>. <br>
            <span style="color: #475569;">[点评]：经典的 SPHINX31 研究，证明了通过 SRPK1 抑制剂改变剪接可以治疗血管生成相关疾病（癌症/眼病）。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Fukuhara T, et al. (2006).</strong> <em>Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.</em> <strong>[[PNAS]]</strong>. <br>
            <span style="color: #475569;">[点评]：发现了 SRPIN340，揭示了 SRPK1 不仅是癌症靶点，也是广谱抗病毒靶点。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Tammaro C, et al. (2020).</strong> <em>SM08502, a novel, small-molecule CDC2-like kinase inhibitor, induces pro-death spliceosome modulation in cancer.</em> <strong>[[Cancer Discovery]]</strong>. <br>
            <span style="color: #475569;">[点评]：临床阶段药物 SM08502 的机制研究，展示了直接干扰剪接体在实体瘤治疗中的潜力。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            SRPK1 抑制剂 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[SRPK1]] • [[CLK]] (协同靶点) • [[SRSF1]] (下游效应子)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">治疗效应</td>
                <td style="padding: 10px 15px; color: #334155;">[[剪接重编程]] • [[抗血管生成]] (VEGF) • [[诱导凋亡]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">代表药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[SRPIN340]] • [[SPHINX31]] • [[SM08502]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">应用领域</td>
                <td style="padding: 10px 15px; color: #334155;">[[前列腺癌]] • [[白血病]] (AML) • [[黄斑变性]] (AMD)</td>
            </tr>
        </table>
    </div>

</div>